var data={"title":"Probenecid: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Probenecid: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6839?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=probenecid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Probenecid: Patient drug information&quot;</a> and <a href=\"topic.htm?path=probenecid-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Probenecid: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213409\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Benuryl</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213442\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Uricosuric Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213413\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hyperuricemia with gout:</b> Oral: 250 mg twice daily for 1 week; may increase to 500 mg twice daily; if needed, may increase to a maximum of 2 g/day (increase dosage in 500 mg increments every 4 weeks). If serum uric acid levels are within normal limits and gout attacks have been absent for 6 months, daily dosage may be reduced  by 500 mg every 6 months. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Prolong penicillin serum levels:</b> Oral: 500 mg 4 times/day. <b>Note:</b> Dosing per manufacturer, see indication-specific dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Neurosyphilis, including ocular syphilis (alternative to preferred therapy) (off-label use):</b> Oral: 500 mg 4 times/day plus procaine penicillin IM for 10 to 14 days (CDC [Workowski 2015]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pelvic inflammatory disease (off-label use):</b> Oral: 1 g as a single dose in combination with cefoxitin IM as a single dose plus oral doxycycline (with or without oral metronidazole) to complete 14 days of therapy (CDC [Workowski 2015])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213428\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=probenecid-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Probenecid: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Contraindicated in children &lt;2 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prolong penicillin serum levels:</b> Children &ge;2 years and Adolescents: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patient weight &le;50 kg: Initial: 25 mg/kg/dose or 700 mg/<b>m</b><b><sup>2</sup></b>/dose as a single dose; maintenance: 40 mg/kg/<b>day</b> or 1,200 mg /<b>m</b><b><sup>2</sup></b><b>/day</b> in 4 divided doses; maximum dose: 500 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patient weight &gt;50 kg: 500 mg 4 times daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213414\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213415\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;\">GFR &lt;30 mL/minute: Avoid use (reduced efficacy with renal impairment)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Probenecid is not recommended as first-line urate-lowering therapy (ULT) monotherapy in patients with renal impairment (CrCl &lt;50 mL/minute) (Khanna 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22464216\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213388\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 500 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213373\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213392\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food to minimize GI effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213391\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of hyperuricemia associated with gout or gouty arthritis; prolongation and elevation of beta-lactam plasma levels</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Guideline recommendations:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Gout:</i> Uricosurics, such as probenecid, are recommended alone or in combination with allopurinol in patients without proper control with allopurinol alone (EULAR [Richette 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744622\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Neurosyphilis, including ocular syphilis; Pelvic inflammatory disease</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213449\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Probenecid may be confused with Procanbid</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213380\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache, pain (costovertebral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia, dermatitis, pruritus, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Gouty arthritis (acute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Anorexia, dyspepsia, gastroesophageal reflux disease, gingival pain, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Hematuria, nephrotic syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, aplastic anemia, hemolytic anemia (in G6PD deficiency), leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hepatic necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Polyuria, renal colic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213395\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to probenecid or any component of the formulation; small- or large-dose aspirin therapy; blood dyscrasias; uric acid kidney stones; children &lt;2 years of age; initiation during an acute gout attack</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213377\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Allergic reaction: Has been associated with rare, severe hypersensitivity reactions, including anaphylaxis.  Discontinue therapy if reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Gout: May cause exacerbation of acute gouty attack.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; G6PD deficiency: Use caution in patients with G6PD deficiency; may increase risk for hemolytic anemia. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Monotherapy may not be effective in patients with a creatinine clearance &lt;30 mL/minute. The American College of Rheumatology guidelines for the treatment of hyperuricemia do <b>not</b> recommend probenecid as first-line or an alternative first-line therapy in patients with a creatinine clearance &lt;50 mL/minute (ACR guidelines [Khanna, 2012]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Methotrexate: Probenecid may increase the serum concentration of methotrexate.  Avoid concomitant use of probenecid and methotrexate if possible. If used together, consider lower methotrexate doses and monitor for  methotrexate toxicity. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Penicillin: Use of probenecid with penicillin in patients with renal insufficiency is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Salicylates: Salicylates may diminish the therapeutic effect of probenecid; this effect may be more pronounced with high, chronic doses, however, the manufacturer recommends the use of an alternative analgesic even in place of small doses of aspirin. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213438\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> MRP2, UGT1A6</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213382\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9812&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: Probenecid may increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anagliptin: Probenecid may increase the serum concentration of Anagliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Avibactam: Probenecid may increase the serum concentration of Avibactam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: MRP2 Inhibitors may increase the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cefotaxime: Probenecid may increase the serum concentration of Cefotaxime.  Management: Avoid cefotaxime doses greater than 6 g/day with concurrent probenecid.  Any patients receiving this combination should be monitored closely for evidence of cefotaxime toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalosporins: Probenecid may increase the serum concentration of Cephalosporins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Systemic): Probenecid may increase the serum concentration of Dapsone (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: UGT1A6 Inhibitors may increase the serum concentration of Deferiprone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: Probenecid may increase the serum concentration of Dexketoprofen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doripenem: Probenecid may increase the serum concentration of Doripenem. This effect is due to probenecid's ability to decrease the active tubular secretion of doripenem. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ertapenem: Probenecid may increase the serum concentration of Ertapenem. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: Probenecid may increase the serum concentration of Ganciclovir-Valganciclovir. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemifloxacin: Probenecid may decrease the excretion of Gemifloxacin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imipenem: Probenecid may increase the serum concentration of Imipenem. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoprofen: Probenecid may increase the serum concentration of Ketoprofen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Nasal): Probenecid may increase the serum concentration of Ketorolac (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketorolac (Systemic): Probenecid may increase the serum concentration of Ketorolac (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Probenecid may enhance the adverse/toxic effect of Loop Diuretics. Probenecid may diminish the diuretic effect of Loop Diuretics. Probenecid may increase the serum concentration of Loop Diuretics.  Management: Monitor for decreased diuretic effects or increased adverse effects of loop diuretics with concomitant use of probenecid. Bumetanide prescribing information recommends against concomitant use of probenecid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LORazepam: Probenecid may increase the serum concentration of LORazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meropenem: Probenecid may increase the serum concentration of Meropenem. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Probenecid may increase the serum concentration of Methotrexate.  Management: Avoid concomitant use of probenecid and methotrexate if possible.  If used together, consider lower methotrexate doses and monitor for evidence of methotrexate toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minoxidil (Systemic): Probenecid may increase the serum concentration of Minoxidil (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Probenecid may increase the serum concentration of Mycophenolate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitrofurantoin: Probenecid may increase the serum concentration of Nitrofurantoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: Probenecid may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oseltamivir: Probenecid may increase serum concentrations of the active metabolite(s) of Oseltamivir.  Management: Consider a change in therapy when using oseltamivir together with probenecid; reduced oseltamivir dose may be necessary.  Increase monitoring for adverse events, such as thrombocytopenia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegloticase: Probenecid may enhance the adverse/toxic effect of Pegloticase. Specifically, Probenecid may blunt increases in serum urate that would signal an elevated risk of anaphylaxis and infusion reactions. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: Probenecid may increase the serum concentration of Penicillins.  Management: Avoid the routine use of penicillins and probenecid, but this combination may be used advantageously in select cases with careful monitoring. Monitor for toxic effects of penicillins if probenecid is initiated or the dose is increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Probenecid may increase the serum concentration of PRALAtrexate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: Probenecid may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, accetaminophen exposure may be increased.  Probenecid may also limit the formation of at least one major non-toxic acetaminophen metabolite, possibly increasing the formation of the toxic NAPQI metabolite.  Management: Consider limiting the use of propacetamide in patients who are also taking probenecid.  Patients may be at an increased risk for toxicity, even if reduced propacetamide doses are used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinolones: Probenecid may decrease the excretion of Quinolones. Specifically, probenecid may decreased the renal excretion of quinolone antibiotics. Probenecid may increase the serum concentration of Quinolones. <b> Exceptions: </b>Moxifloxacin (Systemic).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May diminish the therapeutic effect of Probenecid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Benzoate: Probenecid may increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phenylacetate: Probenecid may increase the serum concentration of Sodium Phenylacetate. Specifically, probenecid may inhibit the renal transport of the phenylacetylglutamine metabolite of sodium phenylacetate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Probenecid may decrease the protein binding of Sulfonylureas. Probenecid may increase the serum concentration of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Probenecid may increase the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Aminophylline; Theophylline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Urea Cycle Disorder Agents: Probenecid may increase serum concentrations of the active metabolite(s) of Urea Cycle Disorder Agents. Specifically, concentrations of phenylacetate and phenylacetylglutamine may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Probenecid may decrease the metabolism of Zidovudine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13108713\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Probenecid crosses the placenta. Based on available data, an increased risk of adverse fetal events have not been reported (Gutman, 2012). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213398\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Drug may cause GI upset; take with food if GI upset. Drink plenty of fluids.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213386\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum uric acid, urinary uric acid, renal function, CBC, frequency of gout attacks (Khanna 2012)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13108716\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Uric acid, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Normal values:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Males: 3.4 to 7 mg/dL or slightly more</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females: 2.4 to 6 mg/dL or slightly more</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Goal during therapy: &lt;6 mg/dL; &lt;5 mg/dL in patients with severe gout (eg, tophi, frequent attacks, chronic arthropathy) (ACR [Khanna 2012]; EULAR [Richette 2017]). Levels &lt;3 mg/dL are not recommended long-term (EULAR [Richette 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Serum uric acid values &gt;7 mg/dL do not necessarily represent clinical gout; current clinical practice guidelines do not address pharmacologic management of asymptomatic hyperuricemia (ACR guidelines [Khanna 2012]; EULAR [Richette 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213376\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitively inhibits the reabsorption of uric acid at the proximal convoluted tubule, thereby promoting its excretion and reducing serum uric acid levels; increases plasma levels of weak organic acids (penicillins, cephalosporins, or other beta-lactam antibiotics) by competitively inhibiting their renal tubular secretion</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213394\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Effect on penicillin levels: 2 hours; Uric acid renal clearance: 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 85% to 95%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination (dose dependent): Normal renal function: 6 to 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 2 to 4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213397\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Probenecid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg (100): $114.56</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F213399\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Benacid (TH);</li>\n      <li>Bencid (IN, TH);</li>\n      <li>Benecid Valdecasas (MX);</li>\n      <li>Benemid (GB, GR, IE, NL, QA);</li>\n      <li>Benemide (FR);</li>\n      <li>Benuryl (IL);</li>\n      <li>Brocid (TW);</li>\n      <li>Gonocilin (BR);</li>\n      <li>Pro-Cid (AU);</li>\n      <li>Probecid (FI, NO, SE);</li>\n      <li>Probecilin (BR);</li>\n      <li>Probenecid Weimer (DE);</li>\n      <li>Probenecid &rdquo;Dak&rdquo; (DK);</li>\n      <li>Probenecid &rdquo;Medic&rdquo; (DK);</li>\n      <li>Procid (TW);</li>\n      <li>Pronid (TW);</li>\n      <li>Santuril (CH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi: 10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/probenecid-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gutman J, Kachur SP, Slutsker L, et al. Combination of Probenecid-Sulphadoxine-Pyrimethamine for intermittent Preventive Treatment in Pregnancy. <i>Malar J</i>. 2012;11:39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/probenecid-drug-information/abstract-text/22321288/pubmed\" target=\"_blank\" id=\"22321288\">22321288</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout. Rheumatology (Oxford). 2007;46(8):1372-4. Available at http://rheumatology.oxfordjournals.org/content/suppl/2008/02/21/kem056a.DC1/kem056b.pdf17522099</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ilett KF, Hackett LP, Ingle B, et al, &ldquo;Transfer of Probenecid and Cephalexin into Breast Milk,&rdquo; <i>Ann Pharmacother</i>, 2006, 40(5):986-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/probenecid-drug-information/abstract-text/16551765/pubmed\" target=\"_blank\" id=\"16551765\">16551765</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khanna D, Fitzgerald JD, Khanna PP, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(10):1431-1446.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/probenecid-drug-information/abstract-text/23024028/pubmed\" target=\"_blank\" id=\"23024028\">23024028</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. <i>Ann Rheum Dis</i>. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/probenecid-drug-information/abstract-text/27457514/pubmed\" target=\"_blank\" id=\"27457514\">27457514</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Ann Rheum Dis</i>. 2014;73(2):328-335.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/probenecid-drug-information/abstract-text/23868909/pubmed\" target=\"_blank\" id=\"23868909\">23868909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Workowski KA, Bolan GA; Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2015 [published correction appears in <i>MMWR Recomm Rep</i>. 2015;64(33):924]. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/probenecid-drug-information/abstract-text/26042815/pubmed\" target=\"_blank\" id=\"26042815\">26042815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). <i>Ann Rheum Dis</i>. 2006;65(10):1312-1324.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/probenecid-drug-information/abstract-text/16707532/pubmed\" target=\"_blank\" id=\"16707532\">16707532</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9812 Version 115.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F213409\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F213442\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F213413\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F213428\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F213414\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F213415\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F22464216\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F213388\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F213373\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F213392\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F213391\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744622\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F213449\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F213380\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F213395\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F213377\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F213438\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F213382\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13108713\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F213398\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F213386\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F13108716\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F213376\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F213394\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F213397\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F213399\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9812|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=probenecid-patient-drug-information\" class=\"drug drug_patient\">Probenecid: Patient drug information</a></li><li><a href=\"topic.htm?path=probenecid-pediatric-drug-information\" class=\"drug drug_pediatric\">Probenecid: Pediatric drug information</a></li></ul></div></div>","javascript":null}